NKMAX

Product Information

Product Type

Monoclonal Antibody

Clone Number

AT6E3

UniProt No.

P00533

NCBI Accession No.

NP_005219

Alternative names

Epidermal growth factor receptor, ERBB, ERBB1, HER1, NISBD2, PIG61, mENA, ERRP, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian)

Product Specification

Host

Mouse

Reacts With

Human

Concentration

1mg/ml (determined by BCA assay)

Formulation

Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol

Immunogen

Recombinant human EGFR (424-605aa) purified from E. coli

Isotype

IgG2b kappa

Purification

By protein-G affinity chromatography

Applications

ELISA, WB, ICC/IF

Usage

The antibody has been tested by ELISA, Western blot and ICC/IF analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

Storage

Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Data

Immunocytochemistry/Immunofluorescence (ICC/IF)

Magnify

ICC/IF analysis of EGFR in HeLa cells. The cell was stained with ATGA0197 (1:100). The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue).

Western blot analysis (WB)

Magnify

The cell lysate(40ug) was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human EGFR antibody (1:1000). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.
Lane .: A431 cell lysate

Related Publications

Tran AV, et al. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers. (Acta Biomater. 2018)
Tran VA, et al. Multimodal Mesoporous Silica Nanocarriers for Dual Stimuli-Responsive Drug Release and Excellent Photothermal Ablation of Cancer Cells. (Int J Nanomedicine. 2020)
Mohamed Isa ED, et al. Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment. (Pharmaceutics. 2021)